Viewing Study NCT03751592


Ignite Creation Date: 2025-12-24 @ 3:57 PM
Ignite Modification Date: 2026-01-31 @ 5:10 AM
Study NCT ID: NCT03751592
Status: UNKNOWN
Last Update Posted: 2018-11-26
First Post: 2018-11-19
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer
Sponsor: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Organization:

Study Overview

Official Title: A Single Arm, Open-label, Multicenter, Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer Patients
Status: UNKNOWN
Status Verified Date: 2018-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This Ib / IIa clinical trial program focuses on the small cell lung cancer (SCLC), Squamous non-small cell lung cancer (NSCLC) and adeniform NSCLC in order to start a better development on the broad-spectrum value of chlorogenic acid: Determine the Disease control rate(DCR)of phase Ib/IIa of Chlorogenic acid for injection in the advanced Lung Cancer Patients.
Detailed Description: 1. Determine the Disease control rate(DCR)of Chlorogenic acid for injection in the advanced Lung Cancer Patients;
2. Determine the Overall Survival(OS)of Chlorogenic acid for injection in the advanced Lung Cancer Patients;
3. Determine the Objective response rate(ORR)of Chlorogenic acid for injection in the advanced Lung Cancer Patients;
4. Determine the Progression Free Survival(PFS)of Chlorogenic acid for injection in the advanced Lung Cancer Patients;
5. Determine Eastern Cooperative Oncology Group(ECOG).

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: